Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST First clinical
Kuros Biosciences AG / Key word(s): Half Year Results Kuros Biosciences reports results for the first six months of 2022 09-Aug-2022 / 17:50 CET/CEST Release of an ad hoc announcement pursuant to
Kuros Biosciences AG / Key word(s): Quarter Results Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft 27-Apr-2022 / 08:07 CET/CEST Release of an ad hoc announcement pursuant
Kuros Biosciences AG / Key word(s): Quarter Results27-Apr-2022 / 08:07 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded.